Havrix Junior (Hepatitis A Virus (Inactivated ) Adsorbed On Aluminium Hydroxide Hydrated Produced On Human Diploid)

Q: What age group is Havrix Junior approved for?

Havrix Junior is approved for use in children aged 12 months and older for hepatitis A prevention.

Q: How many doses of Havrix Junior are required for full protection?

A complete series consists of two intramuscular injections given at least six months apart.

Q: Can Havrix Junior be given together with other childhood vaccines?

It may be administered with inactivated vaccines, but simultaneous use with live attenuated vaccines is generally avoided.

Q: What are the most common side effects after Havrix Junior vaccination?

Common reactions include pain, redness, or swelling at the injection site, low‑grade fever, headache, fatigue, and temporary loss of appetite.

Q: Is Havrix Junior safe for children with a history of severe allergies?

Vaccination should be deferred in children with a known severe allergy to any component of the vaccine, such as aluminium hydroxide.

Q: Should a child who is currently ill receive Havrix Junior?

Vaccination is postponed if the child has an acute moderate or severe illness with fever; mild illness without fever may not require delay.

Q: Can Havrix Junior be given to pregnant or breastfeeding mothers?

Data are limited; vaccination decisions for pregnant or nursing mothers should follow local health authority recommendations.

Q: What serious adverse events have been reported with Havrix Junior?

Rare serious events include severe allergic reactions (anaphylaxis), Guillain‑Barré syndrome, and persistent high fever or severe systemic illness.

Q: Do antipyretics affect the effectiveness of Havrix Junior?

Antipyretics can be used after vaccination to manage fever or discomfort but may mask low‑grade fever; they do not significantly affect immunogenicity.

Q: How long does immunity last after completing the Havrix Junior series?

Clinical studies show that protective antibodies persist for many years, often providing long‑term immunity, though exact duration varies among individuals.

Havrix Junior is an injectable hepatitis A vaccine that contains inactivated hepatitis A virus adsorbed on aluminium hydroxide. It is supplied as a sterile solution for intramuscular administration and is prescribed in the European Union. The vaccine is designed to stimulate active immunity against hepatitis A infection, primarily in pediatric patients, by prompting the body to produce protective antibodies and to contribute to community health protection.

Manufacturer / TM Owner

Glaxosmithkline Biologicals S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Havrix Junior is indicated for the prevention of hepatitis A infection in children and is part of routine immunization schedules in many countries.

Primary prophylaxis against hepatitis A virus in children aged 12 months and older.
Completion of a two‑dose series, typically administered six months apart.
Use in outbreak settings to quickly establish herd immunity among pediatric populations.
Administration before travel to regions where hepatitis A is endemic.
Inclusion in combined vaccination programs when a hepatitis A vaccine is required.

Side Effects

Like other vaccines, Havrix Junior may cause mild to moderate reactions, most of which resolve without medical intervention.

Common

Pain, redness, or swelling at the injection site.
Low‑grade fever (temperature <38.5 °C).
Headache or mild fatigue.
Transient loss of appetite.

Serious

Allergic reactions such as urticaria, angioedema, or anaphylaxis.
Neurological events including Guillain‑Barré syndrome.
Persistent high fever or severe systemic illness.

Precautions & Warnings

Healthcare providers should assess individual risk factors and medical history before administering Havrix Junior to ensure safe vaccination.

Defer vaccination in children with a known severe allergy to any vaccine component, including aluminium hydroxide.
Postpone if the child has an acute moderate or severe illness with fever.
Use caution in individuals with a history of Guillain‑Barré syndrome.
Evaluate immunocompromised patients on a case‑by‑case basis, as response may be reduced.
Discuss pregnancy and breastfeeding status; data are limited, and vaccination decisions should follow local guidelines.
Monitor for signs of anaphylaxis for at least 15 minutes after injection.

Avoid Interactions

Havrix Junior generally has a low potential for drug interactions, but certain concomitant therapies may influence its safety or effectiveness.

Avoid

Simultaneous administration of other injectable vaccines containing live attenuated viruses, which may interfere with immune response.
Use of systemic corticosteroids at immunosuppressive doses immediately before or after vaccination.

Use with caution

Antipyretics (e.g., acetaminophen or ibuprofen) may mask low‑grade fever; they can be given after vaccination if needed.
Immunoglobulin or blood products given within four weeks before or after vaccination may reduce antibody response.
Antihistamines may be used to manage mild allergic reactions but do not prevent serious hypersensitivity.

Frequently Asked Questions